ArticleBlood advances2026
Long-read KIR genotyping reveals donor KIR/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractDonor polymorphisms in killer-cell immunoglobulin-like receptor (KIR) and HLA shape natural killer (NK) cell activity, which may influence relapse risk after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, association studies have been limited by insufficient allele-level KIR genotyping. Using high-resolution, long-read genotyping of 15 KIR genes, we performed an unbiased discovery analysis in 219 patients with T-cell leukemia/lymphoma (ATL) who underwent allo-HSCT to identify relapse-associated donor KIR/HLA polymorphisms. We comprehensively tested associations between donor KIR/HLA amino acid-level combinations and relapse risk, accounting for linkage disequilibrium across KIR haplotypes, and validated the findings in independent cohorts. In ATL, KIR3DL1∗005 or KIR3DS1∗013 with glutamic acid at position 62 in the HLA-B α2 domain (HLA-B-D2-62E) and KIR3DL1∗001/∗007/∗015/∗020 with HLA-B-D2-62V (valine) were high-risk (H) combinations. Meanwhile, KIR3DL1∗015 with isoleucine at position 80 in the HLA-B α1 domain (HLA-B-D1-80I) and KIR3DL1∗001/∗005/∗007/∗020 with HLA-B-D1-80T (threonine) were low-risk (L) combinations. Compared with L-/H+ donors (n = 119), L+/H-, L-/H-, and L+/H+ donors (n = 80) showed reduced relapse (adjusted hazard ratio [HR], 0.36; 95% confidence interval [CI], 0.19-0.65; P = 7.5 × 10-4) and improved overall survival (adjusted HR, 0.67; 95% CI, 0.45-0.98; P = .038). Those donors were associated with reduced relapse in other T-cell malignancies (n = 145; adjusted HR, 0.37; 95% CI, 0.16-0.89; P = .026) but not in acute myeloid leukemia (n = 965; P = .77), suggesting disease specificity. Low-risk combinations increased CD107a degranulation of KIR3DL1+ NK cells against HLA class I-deficient targets, consistent with enhanced NK cell education. These findings support KIR/HLA-based donor selection and underscore the role of antitumor NK cell immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.